磷酸西格列汀对2型糖尿病患者的疗效与安全性观察

42例合用多种VI服药治疗3个月以上血糖控制不佳的超重及肥胖2型糖尿病患者，加服二肽基肽酶Ⅳ抑制剂磷酸西格列汀治疗24周。治疗后，空腹血糖、服糖后2h血糖、糖化血红蛋白均较治疗前有明显下降，分别为（9．3±1．2）降至（6．5±1．9）mmol/L、（15．2±3．1）降至（8．1±2．1）mmol／L、（8．2±2．1）％降至（6．7±1．3）％（均P〈0．01），无低血糖及体重增加等不良反应；血压、血脂、体重较治疗前有下降。提示磷酸西格列汀能有效降低口服降糖药控制不佳的超重及肥胖2型糖尿病患者的血糖水平，具有良好的安全性。

Efficacy and safety of sitagliptin phosphate in type 2 diabetics poorly controlled by antidiabetic drugs

A 24-week study was performed to compare the efficacies of before and after dipeptidyl peptidase-4 inhibitor sitagliptin phosphate 100 mg/d in 42 type 2 diabetics who were inadequately controlled with muhiple oral antidiabetic drugs for at least 3 months. The treatment group sitagliptin phosphate fasting plasma glucose, 2 h postprandial glucose （2 hPPG） and glycated hemoglobulin decreased significantly compared with before treatment [（9.3±1.2） to （6.5 ±1.9） mmol/L, （15.2±3.1） to （8.1 ±2.1） mmoL/L, （8.2±2. 1 ） % to （ 6. 7 ±1.3 ） %, all P 〈 0. 01 ]. There was no hypoglycemia, weight gain or other adverse reactions. The short-term sitagliptin phosphate could effectively reduce the blood sugar levels of poorly controlled obese type 2 diabetics. With a low incidence of hypoglycemia and an excellent safety profile, there was no weight gain.